JT001 (VV116) for the Early Treatment of COVID-19

NCT05242042 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

381

Enrollment

INDUSTRY

Sponsor class

Stopped Based on the current number of COVID-19 cases and the approval of COVID-19 treatment drugs , the research team is facing great challenges, and it is decided to terminate this study

Conditions

Mild to Moderate COVID-19

Interventions

DRUG: JT001
DRUG: Placebo

Sponsor

Shanghai JunTop Biosciences Co., LTD

Collaborators

[object Object]